– USA, CA – Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial-stage biotechnology company, today announced the appointment of Dr. Carol Gallagher (PharmD) to its Board as an independent director.
“I am pleased to welcome Dr. Gallagher to our Board during this pivotal time for the company. Carol brings a tremendous amount of biopharmaceutical and leadership experience, and her insights will be significant as we continue to advance our mission to positively impact the lives of people living with cancer,” said CEO David Meek.
About Dr. Carol Gallagher
Dr. Gallagher has over 30 years of strategic, commercial, business development, and drug development leadership experience in the life sciences industry. Currently, Dr. Gallagher serves as a venture advisor at New Enterprise Associates (NEA), a global venture capital firm. She has also served as a partner with Frazier Healthcare. Previously, Dr. Gallagher was CEO of Calistoga Pharmaceuticals, where she led the company through its acquisition by Gilead Sciences in 2011. Dr. Gallagher has held leadership roles with Eli Lilly, Amgen, Agouron Pharmaceuticals, Pfizer, Idec Pharmaceutics, CancerVax, and Anadys Pharmaceuticals. A veteran board director, Dr. Gallagher currently serves as a board member of PMV Pharma, Atara Biotherapeutics, and, until its recent acquisition by Bristol Myers Squibb in August 2022, Turning Point Therapeutics.
Dr. Gallagher said, “I am thrilled to join the Mirati Therapeutics board of directors during this transformational time for the company. The company’s robust pipeline, coupled with the recently approved KRAZATI, offers the potential to meaningfully impact the lives of people living with cancer. I look forward to the opportunity to share my experience and insight at this important time for Mirati.
Dr. Gallagher attended Vanderbilt University and holds Bachelor of Science and Doctor of Pharmacy degrees from the University of Kentucky. She also serves as a Trustee on the Board of Trustees for the Salk Institute.
About Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc. is a commercial-stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The company is relentlessly focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer. Unified for patients, Mirati’s vision is to unlock the science behind the promise of a life beyond cancer.
Source: https://www.mirati.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.